On 30 July 2024, Bio-Thera Solutions announced that the European Medicines Agency (EMA) has approved Avzivi® (BAT1706), biosimilar to Genentech’s Avastin® (bevacizumab), for treating various cancers.
In September 2021, Bio-Thera and Sandoz entered an agreement under which Sandoz has the commercialisation rights to Avzivi® in Europe, the US, Canada and other international markets. Avzivi® was FDA approved in December 2023 and is approved in China as Pobevcy®.
The first bevacizumab biosimilar was approved in the US in September 2017 and in Europe in January 2018. More recently, in March 2024, Dr Reddy’s launched its Versavo® (bevacizumab) in the UK, five years after its Indian launch.